Evidence map›Paper›PMID 41315961›Full record

ArticleClinical proteomics2025

Comparative evaluation of analytical methods for CSF proteomics.

Aastha Aastha, Leonardo Jose Monteiro De Macedo Filho, Michael Woolman, Vladimir Ignatchenko, Alexander Keszei, Gabriela Remite-Berthet, Alireza Mansouri, Thomas Kislinger

Abstract read
In one paragraph

Article in Clinical proteomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Aastha AasthaDepartment of Medical Biophysics, University of Toronto, Toronto, Canada.
Leonardo Jose Monteiro De Macedo FilhoDepartment of Neurosurgery, Penn State Milton S. Hershey Medical Center, Hershey, PA, USA.
Michael WoolmanPrincess Margaret Cancer Centre, University Health Network, PMCRT, 101 College Street, Room 9-807, Toronto, ON, M5G 1L8, Canada.
Vladimir IgnatchenkoPrincess Margaret Cancer Centre, University Health Network, PMCRT, 101 College Street, Room 9-807, Toronto, ON, M5G 1L8, Canada.
Alexander KeszeiPrincess Margaret Cancer Centre, University Health Network, PMCRT, 101 College Street, Room 9-807, Toronto, ON, M5G 1L8, Canada.
Gabriela Remite-BerthetDepartment of Neurosurgery, Penn State Milton S. Hershey Medical Center, Hershey, PA, USA.
Alireza MansouriDepartment of Neurosurgery, Penn State Milton S. Hershey Medical Center, Hershey, PA, USA. amansouri@pennstatehealth.psu.edu.
Thomas KislingerDepartment of Medical Biophysics, University of Toronto, Toronto, Canada. thomas.kislinger@utoronto.ca.

Funding

Integration of CSF Proteogenomics in the Diagnosis and Management of Diffuse GliomasR01CA279357 · NCI · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI Alireza Mansouri · 2024 to 2026
$1.9M
NCI NIH HHS R01 CA279357NIH HHS 1R01CA279357-01A1
6 · The paper itself

Abstract

Cerebrospinal fluid (CSF) provides a unique window into brain pathology, yet challenges in unbiased mass-spectrometric (MS) discovery persist due to sample complexity and the need for optimized analytical workflows. Multiple laboratory workflows have been developed for CSF proteomics, each with distinct advantages for specific applications. To interrogate which laboratory workflow is most suitable for this biological matrix, we benchmarked five orthogonal sample-preparation strategies- MStern, Proteograph™ nanoparticle enrichment (Seer), N-glycopeptide capture (N-Gp), and two extracellular-vesicle (EV) fractions isolated by differential ultracentrifugation (P20- and P150-EV)- in CSF from 19 patients with central nervous system lymphoma. The protocols span a practical spectrum of input volume (6000-50 µL), hands-on time, and reagent cost, enabling informed method selection for translational applications. In total we performed 82 LC-MS/MS experiments and detected over 38,000 unique peptides and more than 3000 proteins across all modalities. Seer achieved the best proteomic depth (~ 17,000 unique peptides) across samples, followed by P20-EV (~ 9,000), MStern (~ 5,500), P150-EV (~ 5,000), and N-Gp (~ 1,000). None of the methods introduced systematic bias in peptide or protein isoelectric point or hydrophobicity, yet each selectively highlighted distinct biological niches: P20-EVs favoured mitochondrial signatures, N-Gp capture lysosomal and plasma membrane signatures and Seer enhanced nuclear representation. These findings demonstrate that no single protocol suffices for every research question; instead, workflow selection should align with sample-volume constraints, budget and biological question. Our comparative framework empowers investigators to match CSF proteomics strategies to specific neuro-oncological objectives, thereby accelerating the translation of CSF biomarkers into clinically actionable assays.

Identifiers

PMID41315961
PMCPMC12661759

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.